(Weisenthal's note #1: the reviewer's statistics relating to assay performance in the ovarian cancer studies are very misleading. Here are the actual findings in the studies quoted above; references given in a review of CCDRT in ovarian cancer presented elsewhere on this website):

Author             n   Overall RR   RR,"Sensitive"    RR,"Resistant"   Ref (bold clickable)

Weisenthal       3       33%              100%                      0%               [12]
Blackman       72       44%                72%                      4%               [31]
Carstensen     22       27%                60%                      0%               [32]
Ng                 20       31%                50%                      0%               [33]
Konecny        38       54%                66%                    11%               [34]
Ohie              15       53%                88%                    14%               [35]
Sargent          25       42%                60%                    10%               [36]
Sevin             31       81%              100%                    25%               [37]
Sevin             65       77%                94%                    29%               [38]
Taylor            37       46%                65%                    15%               [39]
O'Meara      161       65%                83%                    43%               [40]
Taylor          120 (see linked paper)                                                  [41]
                        
                        Total  N=609,see text 
                        Specificity = 0.92 (Specificity for drug resistance)
                        Sensitivity =  0.72 (Sensitivity for drug resistance)

Return to "the paper reviewed" (ONCOLOGY annonymous review):